Amyloid-β-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 5, 2010, Pages 1101-1112

  Tai, L M ^a   Holloway, K A ^a   Male, D K ^a   Loughlin, A J ^a   Romero, I A ^a  

^a OPEN UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid ; Blood brain barrier; Brain endothelial cells; JNK; Occludin; P38MAPK

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OCCLUDIN; PEPTIDE; PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; OCLN PROTEIN, HUMAN; OCLN PROTEIN, MOUSE;

ARTICLE; BRAIN; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CYTOLOGY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS;

AMYLOID BETA-PROTEIN; BRAIN; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DOWN-REGULATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; TIGHT JUNCTIONS; AMYLOID BETA-PEPTIDES; OCCLUDIN;

EID: 77954711307     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00717.x     Document Type: Article

References (69)

1. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not). Trends Immunol. 2007, 28:5-11.
2. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005, 57:173-85.
3. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res. Commun. 1984, 120:885-90.
4. Klein WL, Stine WB, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging. 2004, 25:569-80.
5. Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 2006, 580:2922-7.
6. Jellinger KA. Cell death mechanisms in neurodegeneration. J Cell Mol Med. 2001, 5:1-17.
7. Rojo LE, Fernandez JA, Maccioni AA. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res. 2008, 39:1-16.
8. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006, 9:151-3.
9. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis. 2008, 5:126-32.
10. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008, 57:178-201.
11. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging. 1997, 18:469-74.
12. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. 2001, 64:575-611.
13. Matsumoto Y, Yanase D, Noguchi-Shinohara M. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr. Cogn Disord. 2007, 23:241-5.
14. Zipser BD, Johanson CE, Gonzalez L. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging. 2007, 28:977-86.
15. Frolich L, Kornhuber J, Ihl R. Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. Eur Arch Psychiatry Clin Neurosci. 1991, 240:363-6.
16. Kay AD, May C, Papadopoulos NM. CSF and serum concentrations of albumin and IgG in Alzheimer's disease. Neurobiol Aging. 1987, 8:21-5.
17. Leonardi A, Gandolfo C, Caponnetto C. The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J Neurol Sci. 1985, 67:253-61.
18. Su GC, Arendash GW, Kalaria RN. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 1999, 818:105-17.
19. Ujiie M, Dickstein DL, Carlow DA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation. 2003, 10:463-70.
20. Blanc EM, Toborek M, Mark RJ. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem. 1997, 68:1870-81.
21. Strazielle N, Ghersi-Egea JF, Ghiso J. In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol. 2000, 59:29-38.
22. Stewart PA, Hayakawa K, Akers MA. A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab Invest. 1992, 67:734-42.
23. Takechi R, Galloway S, Pallebage-Gamarallage MM. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Atherosclerosis. 2008, 9:19-25.
24. Marco S, Skaper SD. Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett. 2006, 401:219-24.
25. Weksler BB, Subileau EA, Perriere N. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19:1872-4.
26. Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem. 2008, 104:859-74.
27. Gravina SA, Ho L, Eckman CB. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995, 270:7013-6.
28. Gonzalez-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008, 1778:729-56.
29. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev. 2001, 2:595-8.
30. Hyman BT, Elvhage TE, Reiter J. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am J Pathol. 1994, 144:565-72.
31. Zhu X, Raina AK, Rottkamp CA. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001, 76:435-41.
32. Zhu X, Rottkamp CA, Boux H. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000, 59:880-8.
33. Berzin TM, Zipser BD, Rafii MS. Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging. 2000, 21:349-55.
34. Elovaara I, Palo J, Erkinjuntti T. Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer's disease and multi-infarct dementia. Eur Neurol. 1987, 26:229-34.
35. Skoog I, Wallin A, Fredman P. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology. 1998, 50:966-71.
36. Wada H. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern Med (Tokyo, Japan). 1998, 37:509-13.
37. Dickstein DL, Biron KE, Ujiie M. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. 2006, 20:426-33.
38. van Oijen M, Hofman A, Soares HD. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006, 5:655-60.
39. Weller RO, Subash M, Preston SD. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol (Zurich, Switzerland). 2008, 18:253-66.
40. Thal DR, Griffin WS, de Vos RA. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 2008, 115:599-609.
41. Balda MS, Whitney JA, Flores C. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol. 1996, 134:1031-49.
42. Chen Y, Merzdorf C, Paul DL. COOH terminus of occludin is required for tight junction barrier function in early Xenopus embryos. J Cell Biol. 1997, 138:891-9.
43. Brooks TA, Hawkins BT, Huber JD. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol 2005, 289:H738-43.
44. Mark KS, Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 2002, 282:H1485-94.
45. Wosik K, Cayrol R, Dodelet-Devillers A. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci. 2007, 27:9032-42.
46. Romanitan MO, Popescu BO, Winblad B. Occludin is overexpressed in Alzheimer's disease and vascular dementia. J Cell Mol Med. 2007, 11:569-79.
47. Patrick DM, Leone AK, Shellenberger JJ. Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma modulate epithelial barrier function in Madin-Darby canine kidney cells through mitogen activated protein kinase signaling. BMC Physiol 2006, 6:2.
48. Lui WY, Wong CH, Mruk DD. TGF-beta3 regulates the blood-testis barrier dynamics via the p38 mitogen activated protein (MAP) kinase pathway: an in vivo study. Endocrinology. 2003, 144:1139-42.
49. Singh AK, Jiang Y, Gupta S. Effects of chronic alcohol drinking on receptor-binding, internalization, and degradation of human immunodeficiency virus 1 envelope protein gp120 in hepatocytes. Alcohol. 2007, 41:591-606.
50. Munoz L, Ranaivo HR, Roy SM. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 2007, 4:21.
51. Bamberger ME, Landreth GE. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. Microsc Res Tech. 2001, 54:59-70.
52. Franciosi S, Ryu JK, Choi HB. Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. J Neurosci. 2006, 26:11652-64.
53. Pyo H, Jou I, Jung S. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport. 1998, 9:871-4.
54. Higuchi Y, Miyakawa T, Shimoji A. Ultrastructural changes of blood vessels in the cerebral cortex in Alzheimer's disease. Jpn J Psychiatry Neurol. 1987, 41:283-90.
55. Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm. 2006, 74:505-30.
56. Abe T, Sugano E, Saigo Y. Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex molecules. Invest Ophthalmol Vis Sci. 2003, 44:4097-104.
57. Afonso PV, Ozden S, Prevost MC. Human blood-brain barrier disruption by retroviral-infected lymphocytes: role of myosin light chain kinase in endothelial tight-junction disorganization. J Immunol. 2007, 179:2576-83.
58. Al-Sadi R, Ye D, Dokladny K. Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol. 2008, 180:5653-61.
59. Mazzon E, Cuzzocrea S. Role of TNF-alpha in lung tight junction alteration in mouse model of acute lung inflammation. Respir Res 2007, 8:75.
60. Okazawa H, Estus S. The JNK/c-Jun cascade and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2002, 17:79-88.
61. Barr RK, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol. 2001, 33:1047-63.
62. Bogoyevitch MA, Arthur PG. Inhibitors of c-Jun N-terminal kinases: JuNK no more. Biochim Biophys Acta. 2008, 1784:76-93.
63. Bogoyevitch MA. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting. Bioessays. 2006, 28:923-34.
64. Morishima Y, Gotoh Y, Zieg J. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci. 2001, 21:7551-60.
65. Fogarty MP, Downer EJ, Campbell V. A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem J. 2003, 371:789-98.
66. Bozyczko-Coyne D, O'Kane TM, Wu ZL. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem. 2001, 77:849-63.
67. Troy CM, Rabacchi SA, Xu Z. beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem. 2001, 77:157-64.
68. Wei W, Wang X, Kusiak JW. Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem. 2002, 277:17649-56.
69. Shen C, Chen Y, Liu H. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem. 2008, 283:17721-30.